Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Phase 3

Not yet recruiting

• Conditions: Endometrial Hyperplasia
• Interventions: Combination Product: BAY865028; Drug: Medroxyprogesterone acetate

• Registration Number: NCT06904274
• Lead Sponsor: Bayer

Brief Summary

Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH).

Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer.

Currently, there are no approved treatments for NAEH and that is why there is still an unmet medical need.

The study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone.

In this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body.

The main purpose of this study is to show that uterine lining goes back to completely normal lining after treatment with Mirena and that its use is safe in this population.

For this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral MPA.

The study participants will be randomly assigned into one of two treatment groups. The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA). Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months.

Each participant will be in the study for around 10 months with up to 5 visits to the study clinic/site.

Participants will visit the study clinic:

* once before the treatment starts

* 3 times with a gap of 3 months between the visits during the treatment

* then 1 more time after the treatment ends

During the study, the doctors and their study team will:

* check participant's health by performing tests such as blood and urine tests

* perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time.

* take samples of womb (endometrial) lining

* ask the participants questions about how they are feeling and what adverse events they are having

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-03-21
• Study First Submitted QC: 2025-03-24
• Study First Posted: 2025-04-01
• Status Verified: 2025-10
• Last Update Submitted: 2025-11-05
• Last Update Posted: 2025-11-06
• Study Start: 2025-12-01
• Primary Completion: 2027-01-20
• Study Completion: 2027-01-20

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 207

Inclusion Criteria

• Post-menarchal women (≥18 years) at the time of signing the informed consent.
• Women with histologically confirmed NAEH independent of their parity or menopausal status.

Exclusion Criteria

• Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results.
• Congenital or acquired uterine or cervical anomaly including fibroids, or cervical stenosis that in the opinion of the investigator, would interfere with insertion and/or retention of the intrauterine system (i.e., if they distort the uterine cavity).
• Use of any long-acting injectable sex-hormone preparations within 6 months prior to the start of study intervention, and /or short acting hormonal medication within 6 weeks prior to the start of study intervention.
• Pregnancy
• Participants with either known family or personal history of genetic predisposition to uterine, ovarian or colorectal cancers (e.g. Lynch syndrome).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Levonorgestrel (BAY865028, Mirena)	BAY865028	Mirena will be inserted into the participant's uterus by the investigator on Day 1. At visit 4 (after 6 months) or if a participant discontinues her study participation prematurely, the Mirena will be removed by the investigator.
Oral progestin	Medroxyprogesterone acetate	Participants will receive 10mg oral progestin once daily, preferably always at the same time of the day, until visit 4 (after 6 months).

Primary Outcome Measures

Name	Time	Method
Proportion of participants with Complete Resolution (CR) of NAEH	At 6 months	Complete Resolution will be evaluated as benign endometrium.

Secondary Outcome Measures

Name	Time	Method
Recurrence of NAEH after CR	At 3 months follow up after 6 months treatment	Recurrence of NAEH on 3 months treatment free after CR at 6 months
Progression after CR	At 3 months follow up after 6 months treatment	Endometrial hyperplasia with atypia or endometrial cancer after 3 months treatment free follow up after CR at 6 months
Proportion of participants having hysterectomy	During treatment and 3 months follow up
Diagnosis of "benign endometrium"	At 6 months of treatment followed by 3 month treatment-free follow up
Number of participants with adverse events	From the signing of the informed consent form (ICF) up to 3 months after the last dose of study intervention	All AEs will be coded using the latest version prior to database lock of the Medical Dictionary for Regulatory Activities

Trial Locations

Locations (71)

Velocity Clinical Research - Mobile; 🇺🇸 Mobile, Alabama, United States

North Valley Women's Care; 🇺🇸 Glendale, Arizona, United States

Velocity Clinical Research - Phoenix; 🇺🇸 Phoenix, Arizona, United States

Alliance Clinical West Hills; 🇺🇸 West Hills, California, United States

K2 Medical Research - South Orlando; 🇺🇸 Orlando, Florida, United States

Entrust Clinical Research; 🇺🇸 Palmetto Bay, Florida, United States

USF Health South Tampa Center for Advanced Healthcare - Gynecology; 🇺🇸 Tampa, Florida, United States

Women's Wellness / SKYCRNG; 🇺🇸 Chicago, Illinois, United States

Hutzel Women's Hospital; 🇺🇸 Detroit, Michigan, United States

SKY integrative Medical Center; 🇺🇸 Ridgeland, Mississippi, United States

Scroll for more (61 remaining)